The estimated Net Worth of Samantha Pearce is at least $2.56 Million dollars as of 2 February 2023. Ms. Pearce owns over 531 units of Jazz Pharmaceuticals plc stock worth over $1,244,739 and over the last 5 years she sold JAZZ stock worth over $1,315,485. In addition, she makes $0 as Senior Vice President und Europe and Rest of World at Jazz Pharmaceuticals plc.
Samantha has made over 9 trades of the Jazz Pharmaceuticals plc stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 531 units of JAZZ stock worth $58,118 on 2 February 2023.
The largest trade she's ever made was exercising 8,508 units of Jazz Pharmaceuticals plc stock on 27 June 2022 worth over $931,201. On average, Samantha trades about 1,180 units every 13 days since 2020. As of 2 February 2023 she still owns at least 11,840 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Ms. Pearce stock trades at the bottom of the page.
Samantha Pearce serves as Senior Vice President, Europe and Rest of World of the Company. Ms. Pearce held various global senior management positions with Celgene Corporation, most recently as Vice President and General Manager, International Markets. Prior to that, from August 2002 to March 2010, she served in management positions at AstraZeneca plc, culminating in her role as Director, Specialist Care. Prior to August 2002, she worked for DuPont Pharmaceuticals.
Samantha Pearce is 54, she's been the Senior Vice President und Europe and Rest of World of Jazz Pharmaceuticals plc since 2020. There are 15 older and 12 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
Samantha's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright und Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: